Strength of the Evidence: Adjuvant Therapy for Resected Pancreatic Cancer

被引：0

作者：

Vincent J. Picozzi

Peter W. T. Pisters

Selwyn M. Vickers

Steven M. Strasberg

机构：

[1] Virginia Mason Medical Center,Section of Medical Oncology

[2] Barnes Hospital,Section of General Surgery

[3] MD Anderson Hospital,Section of Surgical Oncology

[4] University of Minnesota,Deparment of Surgery

来源：

Journal of Gastrointestinal Surgery | 2008年 / 12卷

关键词：

Pancreatic cancer; Adjuvant therapy; Postgraduate course; Pancreatic neoplasms;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Pancreatic cancer remains one of the greatest challenges within oncology. Among resected patients, 5-year survival is typically only 10–25%. Among eight major randomized trials for resected pancreas cancer, five (GITSG, EORTC, ESPAC-1, RTOG 9704, and CONKO-1), containing a total of over 1,200 patients, have shaped world opinion on this subject. These trials have many significant methodological differences. Major conclusions that can be drawn from these trials in composite are (1) adjuvant chemotherapy is superior to observation following pancreaticoduodenectomy for pancreatic cancer, (2) gemcitabine is superior to 5-FU as adjuvant chemotherapy, and (3) the benefit of adjuvant chemoradiation is uncertain. Additional randomized trials are needed to address significant areas of controversy within available data.

引用

页码：657 / 661

页数：4

共 50 条

[1] Strength of the evidence: Adjuvant therapy for resected pancreatic cancer
Picozzi, Vincent J.
Pisters, Peter W. T.
Vickers, Selwyn M.
Strasberg, Steven M.
[J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (04) : 657 - 661
[2] Adjuvant therapy in resected pancreatic cancer
Neoptolemos, J. P.
[J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S4 - S4
[3] Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?
Fenocchio, Elisabetta
Filippi, Roberto
Lombardi, Pasquale
Quara, Virginia
Milanesio, Michela
Aimar, Giacomo
Leone, Francesco
Aglietta, Massimo
[J]. CANCERS, 2019, 11 (10)
[4] Results of adjuvant therapy in resected pancreatic cancer
Åke Andrén-Sandberg
Pia Lena Bäckman
Roland Andersson
[J]. International journal of pancreatology, 1997, 21 (1) : 31 - 38
[5] Results of adjuvant therapy in resected pancreatic cancer
AndrenSandberg, A
Backman, PL
Andersson, R
[J]. INTERNATIONAL JOURNAL OF PANCREATOLOGY, 1997, 21 (01) : 31 - 38
[6] Completion of adjuvant therapy in patients with resected pancreatic cancer
DePeralta, Danielle K.
Ogami, Takuya
Zhou, Jun-Min
Schell, Michael J.
Powers, Benjamin D.
Hodul, Pamela J.
Malafa, Mokenge P.
Fleming, Jason B.
[J]. HPB, 2020, 22 (02) : 241 - 248
[7] VEGF, angiogenesis and adjuvant therapy outcomes in resected pancreatic cancer.
Khorana, AA
Hu, YC
Ryan, CK
Komorowski, RA
Hostetter, G
Ahrendt, SA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 315S - 315S
[8] Survival benefit with adjuvant radiation therapy in surgically resected pancreatic cancer
Greco, J. A.
Castaldo, E. T.
Feurer, I. D.
Pinson, C. W.
Chakravarthy, A. B.
Merchant, N. B.
Parikh, A. A.
[J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 108 - 109
[9] Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer A Meta-analysis
Yu, Zhong
Zhong, Wa
Tan, Zhi-Ming
Wang, Ling-Yun
Yuan, Yu-Hong
[J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (03): : 322 - 325
[10] Adjuvant therapy for surgically resected pancreatic adenocarcinoma
Abbruzzese, James L.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (09): : 1066 - 1067

← 1 2 3 4 5 →